Sanofi Ends Trial for E. Coli Shot and Takes a $250 Million Hit
Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an ...
pharmaphorum5d
Sanofi will exit consumer health and boost R&D investment
In its third-quarter results update, Sanofi said the consumer health unit – which owns brands like allergy therapies Allegra and Xyzal, irritable bowel syndrome product Buscopan, painkiller ...
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Bullous Pemphigoid
Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...
Sanofi in exclusive talks with CD&R over sale of $17 bn Opella
Allegra allergy treatments and Buscopan pain relief. Sanofi, which said a year ago it was reviewing separation scenarios for ...
FiercePharma28d
Sanofi's consumer health arm Opella secures FDA green light to pursue OTC Cialis study
stomach cramp reliever Buscopan and pain treatments Icy Hot and Gold Bond, among others. While Opella has long operated as a standalone unit within Sanofi, boasting more than 11,000 employees ...